http://www.tevapharm.com/Media/News/Pages/2012/1739032.aspx I guess Lundbeck can spend $200 million upfront just for the "opportunity" to sell Abilify depot, in a crowded antipsychotic market in the US, but it can't invest $26 million to commercialize the most promising HD product currently in development. The clock is winding down on Xenazine in the US. Denmark, where is the long term commitment to HD now that you have milked hundreds of millions of dollars out of the US taxpayer with a decades old drug?
